Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237729 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 362
- Enrollment target
NCT02237729: Completed Phase 1 study, sponsored by Pfizer.
NCT02237729 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 362 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (503% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02237729, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 362 participants
- Enrollment target
Study Summary
This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers
Primary Outcome
maximal serum concentration (Cmax)
Interventions
- BIOLOGICAL PF-06410293
- BIOLOGICAL Adalimumab-US
- BIOLOGICAL Adalimumab-EU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT02237729 record still lists
NCT02237729 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (503% higher).
The record links to 0 conditions, and to 3 interventions - of which PF-06410293 is the first listed.
NCT02237729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02237729 about?
NCT02237729 is a clinical study titled "A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))". This is a Phase 1, double blind (sponsor open), randomized (1:1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers
What is the current status of trial NCT02237729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 362 participants. The study started on 2014-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02237729?
The interventions under investigation include: PF-06410293 (BIOLOGICAL), Adalimumab-US (BIOLOGICAL), Adalimumab-EU (BIOLOGICAL).
Who is sponsoring clinical trial NCT02237729?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02237729's enrollment target sits among peer trials
362 90th of 2000 higher than 1,910 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia